Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. blms 4 tb

BLMs 4 TB SIGNED

Beta-lactams for Tuberculosis Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BLMs 4 TB project word cloud

Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.

urgently    therapy    patients    leads    agents    pd    therapies    generation    combo    extensively    frequency    unpleasant    anti    pharmacodynamics    prevent    linked    record    never    treatment    led    lactams    safest    relapse    severe    cephems    quality    hope    shorten    infections    disease    pursued    killing    inform    proteomic    trial    meropenem    prospects    decades    24    specificities    garc    treat    outcomes    arose    market    carbapenem    trials    dosage    life    adherence    track    dr    tb    cephalosporins    regarded    longer    oacute    pharmacokinetic    microscopy    infected    techniques    glaxosmithkline    resistance    pk    mathematical    last    iacute    bacterial    modeling    strains    virtually    dim    family    infectious    data    xdr    outcome    ineffective    undergo    ram    renewed    time    iia    beta    questions    answer    positive    blm    treatments    blms    clinical    administration    molecular    first    deadly    50    head    tuberculosis    report    worldwide    point    unclear    gsk    validated    optimal    transcriptomic    microbiology    discontinued    subset    resistant    beneficiary    barros    lapse    carbapenems    antibiotics    takes    mdr    months    drug    poor   

Project "BLMs 4 TB" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO 

Organization address
address: PASEO MARIA AGUSTIN 36 EDIFICIO PIGNATELLI PTA 30 PL 2
city: ZARAGOZA
postcode: 50004
website: www.araid.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO ES (ZARAGOZA) coordinator 170˙121.00

Map

 Project objective

Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.

Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.

Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.

To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

EngPTC2 (2019)

Exploring new technologies for the next generation pulse tube cryocooler below 2K

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More